“These findings show that HIV patients are being unfairly perceived to have worse kidney transplant outcomes than noninfected groups, and as a result, they often have to wait the longest for transplants and there are fewer living donors,” Deirdre Sawinksi, MD, assistant professor in the division of renal, electrolyte and hypertension at the Perelman School of Medicine, University of Pennsylvania, said in a press release. “Our hope is that these study findings result in greater access to transplantation for HIV patients, while also inspiring the kidney transplant community to focus on eradicating hepatitis C in transplant patients — either pre-transplant or if that’s not possible, immediately post-transplant — to ensure better outcomes for these patients.”
“Under current U.S. kidney transplant practice, HIV monoinfection does not adversely affect recipient or allograft survival and is associated with superior outcomes compared with both HCV monoinfection and HIV/HCV coinfection in this population,” the researchers concluded. “Investigation of pretransplant or immediate post-transplant viral eradication with contemporary therapies should be prioritized as a strategy to improve post-transplant outcomes in HCV-infected kidney recipients.” – by Melinda Stevens
No comments:
Post a Comment